二氨藜芦啶 - CAS:5355-16-8 - CAS号查询_生物试剂_化学试剂_分析试剂

中文名称:	二氨藜芦啶
英文名称:	Diaveridine
别名:	5-(3,4-二甲氧苄基)-2,4-嘧啶二胺 EGIS-5645
CAS No:	5355-16-8	分子式:	C₁₃H₁₆N₄O₂	分子量:	260.29
CAS No:	5355-16-8
分子式:	C₁₃H₁₆N₄O₂
分子量:	260.29
MDL:	MFCD00057349	EINEC:	226-333-3
EINEC:	226-333-3

安全技术说明书(PDF) MSDS(PDF) 点击下载产品说明书(PDF) 点击下载技术规格说明书(PDF)

D10610 二氨藜芦啶 ≥98% (psaitong)

相关产品

甲氨蝶呤水合物
CAS No：133073-73-1
培美曲塞二钠水合物
CAS No：357166-30-4
N5-甲基四氢叶酸钙
CAS No：26560-38-3
TNP-351
CAS No：125991-51-7
Methotrexate metabolite
CAS No：19741-14-1
普拉曲沙
CAS No：146464-95-1

包装规格：

1g 5g 25g in glass bottle

溶解性：

溶于DMSO（32 mg/mL 超声)

产品描述：

基本信息

产品编号：D10610
产品名称：Diaveridine
CAS:	5355-16-8	储存条件	粉末	2-8℃	四年

分子式：	C13H16N4O2		溶于液体	-80℃	两年
分子量	260.29			-20℃	一个月
化学名：	2,4-Diamino-5-(3,4-dimethoxybenzyl)pyrimidine
Solubility (25°C)	体外	DMSO	25mg/mL (96.04mM)
		Ethanol
		Water
	体内	现配现用
＜1mg/ml表示微溶或不溶。
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

制备储备液

浓度溶液体积质量	1mg	5mg	10mg
1mM	3.8419mL	19.2093mL	38.4187mL
5mM	0.7684mL	3.8419mL	7.6837mL
10mM	0.3842mL	1.9209mL	3.8419mL
50mM	0.0768mL	0.3842mL	0.7684mL

生物活性

产品描述	二氢叶酸还原酶 (DHFR) 的抑制剂，对于野生型 DHFR 的 Ki 值为 11.5nM，Diaveridine 也是一种抗菌剂。
靶点/IC₅₀	Ki: 11.5nM (DHFR) Bacterial
体外研究	Diaveridine is a dihydrofolate reductase (DHFR) inhibitor with a Ki of 11.5 nM for the wild type DHFR and also an antibacterial agent. Treatments with Diaveridine for 90 min have a strong bactericidal effect on S. typhimurium TA1535, and no bacterial growth is observed at 10μg/mL or more. Without metabolic activation, treatment with Diaveridine for 48 h, but not 24 h, causes a dose-dependent, significant increase in the frequency of aberrant metaphases. At 100 μg/mL, 60% of the metaphases contain chromosome aberrations.
体内研究	The sperm abnormality of the Diaveridine (DVD) treatment groups at all dose levels (Diaveridine, 128 to 512 mg/kg) shows no significant differences compare with the negative control group. There are no significant differences of micronucleus between the negative control group and the Diaveridine treatment groups (Diaveridine, 128 to 512mg/kg). The chromosome aberration of the Diaveridine treatment groups at all dose levels and the negative control group are significantly lower than those in the positive control group treated with cyclophosphamide (P<0.05), indicating that Diaveridine at the doses studied does not cause abnormal chromosome aberration. The results demonstrate that the Diaveridine administration does not produce significant changes in the ratio of organ-to-body weight, compare with the negative control group in the end period of the study.

推荐实验方法(仅供参考)

细胞实验：

Cell Assay

Cells are cultured at 37°C in a humidified atmosphere of 5% CO2 in air. The growth medium is Eagle’s MEM supplemented with 10% fetal bovine serum. In the experiment without metabolic activation, the cells are treated for 24 or 48 h continuously without a medium change. In the experiment with metabolic activation, the cells are pulse treated with test compounds (including Diaveridine) at varying doses for 6 h and incubated for 18 h in fresh culture medium. Breakage type chromatid aberrations, exchange type chromatid aberrations, breakage type chromosome aberrations, and exchange type chromosome aberrations are scored. Gaps are also counted. Mitotic index is determined from scoring 2000 cells.

动物实验:

Animal Administration

3]Fifty male ICR mice, weighing 25 to 35 g, are assigned to five groups randomly with 10 mice in each group. Mice in the experiment groups receive Diaveridine (DVD) via IG at ed 128 mg/kg (low doses), 256mg/kg (medium doses), and 512 mg/kg (high doses) body weight for 5 consecutive days, respectively. Mice in negative and positive control groups receive IG 1% CMC-Na solvent and 40 mg/kg body weight of cyclophosphamide, respectively. The testing groups are administered 0.2mL/10 g Diaveridine (mixed with 1% of CMC-Na, to obtain the concentration of 2mg/mL.) body weight, once a day, for 5 days. The behavioral changes are recorded on the daily basis.

保存条件：

2-8℃

UN码：

HazardClass：

危害声明：

安全说明：

点击下载核磁/氢谱图谱(PDF)

点击下载高效液相/气相图谱(PDF)

搜索质检报告(COA)

参考文献 & 客户发表文献